Tirzepatide 20mg

$110.00

Tirzepatide is a potent dual GLP‑1 / GIP agonist approved for diabetes and obesity weight‑loss.
Standard dose escalation: start at 2.5 mg/week, increase gradually. Maintenance doses generally go up to 15 mg/week. Going beyond that is off‑label.
“20 mg” vials/pens are used for supply or concentration, not necessarily to denote a weekly dose.

Description

Tirzepatide 20mg (brand names include Mounjaro, Zepbound) is a dual agonist of the GLP‑1 (Glucagon‑Like Peptide‑1) and GIP (Glucose‑Dependent Insulinotropic Polypeptide) receptors. It helps with glucose control, appetite suppression, weight loss, and improved metabolic health.

Official approved regimens for tirzepatide typically do not go up to 20 mg per week. The maintenance doses used in clinical practice and by NICE (UK) are 5 mg, 10 mg, and 15 mg once weekly.
The 20 mg figure often seen in some products refers to either:
1. Concentration (how many mg per mL), which affects how much volume is injected for a given dose. Higher vials mean smaller injection volumes for the same mg dose. Misunderstanding concentration vs. dose is a common source of error.

According to prescribing and official guidance (e.g., NICE in the UK):

Phase	Dose (once weekly)	When to Increase
Start	2.5 mg/week	After 4 weeks
Maintenance Increments	Then increase in 2.5 mg steps: 5 mg → 10 mg → 15 mg	Each increase after at least 4 weeks, depending on tolerability and response.